Ország: Írország
Nyelv: angol
Forrás: HPRA (Health Products Regulatory Authority)
Estradiol; Norethisterone acetate
PCO Manufacturing Ltd.
G03FA01
Estradiol; Norethisterone acetate
1 mg/0.5 milligram(s)
Film-coated tablet
Product subject to prescription which may be renewed (B)
norethisterone and estrogen
Authorised
2007-10-19
_ _ PACKAGE LEAFLET: INFORMATION FOR THE USER ACTIVELLE ® 1 MG/0.5 MG FILM-COATED TABLETS estradiol/norethisterone acetate READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU – Keep this leaflet. You may need to read it again. – If you have any further questions, ask your doctor or pharmacist. – This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. – If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Activelle is and what it is used for 2. What you need to know before you take Activelle 3. How to take Activelle 4. Possible side effects 5. How to store Activelle 6. Contents of the pack and other information 1. WHAT ACTIVELLE IS AND WHAT IT IS USED FOR Activelle is a continuous combined Hormone Replacement Therapy (HRT). It contains two types of female hormones, an oestrogen and a progestagen. Activelle is used in postmenopausal women with at least 1 year since their last natural period. Activelle is used for: RELIEF OF SYMPTOMS OCCURRING AFTER MENOPAUSE During the menopause, the amount of oestrogen produced by a woman’s body drops. This can cause symptoms such as hot face, neck and chest (‘hot flushes’). Activelle alleviates these symptoms after menopause. You will only be prescribed Activelle if your symptoms seriously hinder your daily life. PREVENTION OF OSTEOPOROSIS After the menopause some women may develop fragile bones (osteoporosis). You should discuss all available options with your doctor. If you are at an increased risk of fractures due to osteoporosis and other medicines are not suitable for you, you can use Activelle to prevent osteoporosis after menopause. Activelle is prescribed for women who have not had their womb removed, and whose periods stopped more than a year ago. There is only limited ex Olvassa el a teljes dokumentumot
Health Products Regulatory Authority 23 October 2023 CRN00DV65 Page 1 of 2 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Activelle 1 mg/0.5 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains: Estradiol 1 mg (as estradiol hemihydrate) and norethisterone acetate 0.5 mg. Excipient with known effect: lactose (as monohydrate). For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet _ _ _Product imported from Italy, Poland and Czech Republic:_ White, film-coated, round tablets with a diameter of 6 mm, engraved with 'NOVO 288' on one side and the _Novo Nordisk _bull logo on the other. 4 CLINICAL PARTICULARS As per PA0218/052/001 5 PHARMACOLOGICAL PROPERTIES As per PA0218/052/001 6 PHARMACEUTICAL PARTICULARS 6.1 LIST OF EXCIPIENTS Tablet core: Lactose monohydrate Maize starch Copovidone Talc Magnesium stearate Film-coating: Hypromellose Triacetin Talc 6.2 INCOMPATIBILITIES Not applicable. 6.3 SHELF LIFE The shelf-life expiry date of this product shall be the date shown on the container and outer package of the product on the market in the country of origin. Health Products Regulatory Authority 23 October 2023 CRN00DV65 Page 2 of 2 6.4 SPECIAL PRECAUTIONS FOR STORAGE Do not store above 25°C. Do not refrigerate. Keep the container in the outer carton in order to protect from light. 6.5 NATURE AND CONTENTS OF CONTAINER 1 x 28 tablets in a calendar dial pack. 6.6 SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER HANDLING Any unused medicinal product or waste material should be disposed of in accordance with local requirements. 7 PARALLEL PRODUCT AUTHORISATION HOLDER PCO Manufacturing Ltd. Unit 10, Ashbourne Business Park Rath Ashbourne Co. Meath Ireland 8 PARALLEL PRODUCT AUTHORISATION NUMBER PPA0465/199/001 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 19th October 2007 10 DATE OF REVISION OF THE TEXT October 2023 Olvassa el a teljes dokumentumot